louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01102179: Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease (CKD) Patients in Singapore
Official title: Prevalence of Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease Patients in Singapore
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stage 2-5 Chronic Kidney Disease
Predialysis
Lead sponsor: National University of Singapore
Sponsor class: OTHER
Collaborators: name: National Kidney Foundation, Singapore
First posted: 2010-04-13
Enrollment: 196
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with stage 2-5 chronic kidney disease who are not on dialysis

Brief summary: Vitamin D insufficiency and deficiency is common in chronic kidney disease (CKD) patients and is associated with elevated parathyroid hormone (PTH) concentration and mineral and bone disorder (MBD). There is also increasing evidence to show that these abnormalities increase cardiovascular morbidity and mortality in CKD patients. There is a need for early identification of vitamin D insufficiency/deficiency in CKD patients to prevent its long-term complications. However, the vitamin D status of CKD patients in Singapore has not been well described. The purpose of this study is to assess the vitamin D status of predialysis CKD patients in a tertiary academic teaching hospital in Singapore, and its association with parameters for MBD. Predialysis patients from the outpatient renal clinic at the National University Hospital (NUH) will be recruited into this study. Blood samples from the patients will be collected after an overnight fast to determine their serum 25(OH)D, creatinine, phosphorus, calcium, albumin and i-PTH concentrations. These parameters will be compared among patients in various stages of CKD.


Eligibility criteria: Inclusion Criteria:

* Male or female 21 years of age or older
* CKD stage 2 to 5 (who are not on dialysis): CKD stage 2: eGFR 60-89ml/min/1.73m2, stage 3: eGFR 30-59ml/min/1.73m2, stage 4: eGFR 15-29 ml/min/1.73m2, stage 5 eGFR \<15 ml/min/1.73m2)
* Not receiving over-the-counter or prescription vitamin D therapy
* On a stable dose of phosphate binder (if any) for at least 1 month prior to the study

Exclusion Criteria:

* History of liver and chronic inflammatory diseases, primary hyperparathyroidism and malignancies
* Use of corticosteroids, anticonvulsants or vitamin D compounds
* Use of an investigational agent within 30 days of study entry

Primary outcomes:
measure: Vitamin D 25(OH)D levels
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University Hospital
Study officials:
affiliation: National University of Singapore/National University Hospital
name: Priscilla P How, Pharm.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04582279: Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Lung Transplant Recipients
Official title: Application of Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Asymptomatic Lung Transplant Recipients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Post-Lung Transplantation Bronchiectasis
Keywords: Post lung transplant
Lung bronchoscopy
Lung biopsy
Lung rejection
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2020-10-09
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: There is only 1 group of participants being monitored. Every patient will follow the same study procedures
Primary purpose: DIAGNOSTIC

Brief summary: This study is being done to study a safe and non-invasive way to diagnose lung rejection and infection.

Detailed description: Lung transplant recipients are at high risk for lung rejection and lung infection after transplant. This is diagnosed by performing lung bronchoscopies and lung biopsies. These procedures carry an increased risk for complications and are costly. This study is being done to study a safe and non-invasive way to diagnose lung rejection and infection.

Eligibility criteria: Inclusion Criteria:

* Adult patients (\> 18 yrs) who had undergone single/double/heart-lung transplant
* Asymptomatic
* Normal spirometry defined as a FEV1 without significant drop from baseline (significant drop = \>10% decrease from baseline)
* Clear chest radiograph over allograft

Exclusion Criteria:

* Patients who are unable to consent for the procedure
* Patients with subcutaneous emphysema or other technical challenges that could interfere with satisfactory image acquisition- as deemed by the operator.

Primary outcomes:
measure: Establish predictive value of lung ultrasound
timeFrame: Month 0 to month 12
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Tathagat Narula, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03335579: General Anesthetic Mode and Postoperative Complications
Official title: Relationship Between General Anesthetic Mode and Postoperative Severe Cardiovascular and Cerebrovascular Complications: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2017-11-07
Enrollment: 50000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients for non-cardiac surgery under general anesthesia

Brief summary: The relationship between anesthetic medication and postoperative major cardiac and cerebral complications will be studied using logistic regression model.

Detailed description: The study group try to find out if there is a connection between the use of different anesthetic methods with different narcotic drugs and postoperative major cardiac and cerebral complications.

Eligibility criteria: Inclusion Criteria:

* non-cardiac surgery, with age\> = 18 years old, ASA grade I-IV, under general anesthesia

Exclusion Criteria:

* non-general anesthesia, without the use of target-controlled infusion of remifentanil or sufentanil, absence of intraoperative or perioperative information.

Primary outcomes:
measure: Major cardiac complication
timeFrame: 90 days after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Herling SF, Dreijer B, Wrist Lam G, Thomsen T, Moller AM. Total intravenous anaesthesia versus inhalational anaesthesia for adults undergoing transabdominal robotic assisted laparoscopic surgery. Cochrane Database Syst Rev. 2017 Apr 4;4(4):CD011387. doi: 10.1002/14651858.CD011387.pub2.
citation: Flier S, Post J, Concepcion AN, Kappen TH, Kalkman CJ, Buhre WF. Influence of propofol-opioid vs isoflurane-opioid anaesthesia on postoperative troponin release in patients undergoing coronary artery bypass grafting. Br J Anaesth. 2010 Aug;105(2):122-30. doi: 10.1093/bja/aeq111. Epub 2010 Jun 23.
citation: Min JJ, Kim G, Lee JH, Hong KY, Kim WS, Lee YT. Does the Type of Anesthetic Technique Affect In-Hospital and One-Year Outcomes after Off-Pump Coronary Arterial Bypass Surgery? PLoS One. 2016 Apr 7;11(4):e0152060. doi: 10.1371/journal.pone.0152060. eCollection 2016.
citation: Guclu CY, Unver S, Aydinli B, Kazanci D, Dilber E, Ozgok A. The effect of sevoflurane vs. TIVA on cerebral oxygen saturation during cardiopulmonary bypass--randomized trial. Adv Clin Exp Med. 2014 Nov-Dec;23(6):919-24. doi: 10.17219/acem/37339.
Clinical trial NCT02858479: Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic
Official title: Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neuropathic Pain
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2016-08-08
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Neuropathic pain is a medical condition involving allodynia (painful perceptions in response to stimuli that normally are not) and spontaneous pain (occurring at rest, without stimulation).

This pain is secondary to nervous system injury affecting the sensory system. The lesion is either at the nerve endings of the spinal cord or brain. It induces a loss of sensitivity and reorganization of brain activity.

Previous studies in functional neuroimaging have focused on brain areas activated during allodynic stimuli compared to non-painful stimuli. The abnormalities have been reported, but it was not possible to conclude formally.

The objective of this study is to understand the brain dysfunction that induces allodynic pain considering the deafferentation of each patient and possible cortical losses.


Eligibility criteria: Inclusion Criteria:

* with neuropathic pain
* in the case of central lesions, the lesion must be unique and small
* treatment not stable opioid for one week
* consent signed

Exclusion Criteria:

* severe psychiatric history
* presence of an evolutive lesion, expansive, cancerous or tumorous underlying
* patient needing of opioid therapy
* contraindication at MRI scan

Primary outcomes:
measure: the deafferentation rate
timeFrame: at baseline
measure: gray matter rate
timeFrame: at baseline
Secondary outcomes:
measure: Analysis pain
timeFrame: at baseline
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: CHU de SAINT-ETIENNE
Study officials:
affiliation: CHU de SAINT-ETIENNE
name: Roland PEYRON, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01002079: Drug-Drug Interaction Study With Rifampin
Official title: A Study of the Effect of Concomitant Administration of Rifampin on the Pharmacokinetics of BMS-708163 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
Collaborators: name: PRA Health Sciences
First posted: 2009-10-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin


Eligibility criteria: Inclusion Criteria:

* Healthy male and postmenopausal female subjects, 18-55 yrs old inclusive

Exclusion Criteria:

* Women of childbearing potential
* Tuberculosis

Primary outcomes:
measure: BMS-708163 alone and with rifampin: BMS-708163 single dose PK parameters (Cmax, Tmax, T-HALF, AUC(0-T), AUC(INF), CLT/F and molar AUCmet/AUCparent ratios will be assessed without rifampin (Day 1) and with rifampin (Day 13)
timeFrame: Within 30 days after dose
Secondary outcomes:
measure: BMS-708163 alone and with rifampin: Safety and tolerability (AE's, ECG, vital signs, safety labs)
timeFrame: Within 30 days after dose
Other outcomes:
Locations:
city: Bangalore
country: India
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT01081379: The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection
Official title: The Relation Between the Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pregnant Women
Cytomegalovirus Infections
Keywords: Cytomegalovirus Infections
Pregnancy
T-Lymphocytes
Transmission
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2010-03-05
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women with primary CMV

Brief summary: The purpose of this study is to find a correlation between function of cytomegalovirus -specific T cells and the probability for intrauterine transmission.

Detailed description: Fetal infection with CMV is the most common cause of intrauterine infection. Only 40% of pregnant women with primary CMV transmit the virus to their fetus. Many of these women are referred to amniocentesis and many elect to terminate pregnancy without knowledge about fetal infection or damage. Currently it is assumed that transmission is dictated by variety of factors including maternal and fetal immune system. Efforts to find correlation between maternal immune system and fetal infection which can be used as a diagnostic marker were unsuccessful.

Our hypothesis is that there is a correlation between cellular immune response of the mother to CMV infection and viral transmission to the fetus.

Pregnant women with primary CMV infection (40% of whom are expected to be transmitters)and with pre-conception immunity will participate in this study.

Blood from these women will be incubated with CMV peptides and T cell activation will be measured by the secretion of various cytokines.

Eligibility criteria: Inclusion Criteria:

* Pregnant women
* CMV IgG sero-conversion or the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies.

Exclusion Criteria:

* Underlying immune deficiencies
* Other pregnancy complications

Primary outcomes:
measure: Maternal-Fetal transmission of CMV
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
affiliation: Shaare Zedek Medical Center
name: Yechiel Schlesinger, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02997579: Comparison of Vibration Arthrometry Between Patella Resurfacing and Patella Non-resurfacing in Total Knee Replacement Patients
Official title: Prospective Randomized Controlled Trial: Comparison of Vibration Arthrometry Between Patella Resurfacing and Patella Non-resurfacing in Total Knee Replacement Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patellar Crepitus
Vibroacoustic Signal
Lead sponsor: Navamindradhiraj University
Sponsor class: OTHER
First posted: 2016-12-20
Enrollment: 102
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Patellar crepitus is a complication of total knee arthroplasty (TKA).The development of patellar crepitus after TKA are related to many factors such as femoral component design, surgical errors, and postoperative patellar baja. However, it is unclear whether patella resurfacing or patella non-resurfacing are associate with patellar crepitus. The primary objective of this study are to compare the prevalence of patellar crepitus and the mean value of vibroacoustic signal between patellar-resurfacing and patellar non-resurfacing in TKA. The secondary objective is to study the association between patellar crepitus and vibroacoustic signal.


Eligibility criteria: Inclusion Criteria:

* primary osteoarthritis of knee

Exclusion Criteria:

* rheumatoid arthritis
* morbid obesity
* severe patellofemoral joint destruction
* patella maltracking
* patellofemoral incongruent
* inflammatory arthritis
* refuse to participation

Primary outcomes:
measure: change of patellar crepitus
timeFrame: pre-op, 3, 6 month
measure: change of mean of vibroacoustic signal
timeFrame: pre-op, 3, 6 month
Secondary outcomes:
measure: Number of patellar crepitus related to mean of vibroacoustic signal
timeFrame: pre-op, 3, 6 month
Other outcomes:
Locations:
city: Dusit
country: Thailand
facility: Navamindradhiraj University
state: Bangkok
Study officials:
affiliation: Department of Orthopaedics, Faculty of Medicine Vajira Hospital, Navamindradhiraj University
name: Satit Thiengwittayaporn, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Baczkowicz D, Majorczyk E. Joint motion quality in vibroacoustic signal analysis for patients with patellofemoral joint disorders. BMC Musculoskelet Disord. 2014 Dec 12;15:426. doi: 10.1186/1471-2474-15-426.
citation: Tanaka N, Hoshiyama M. Vibroarthrography in patients with knee arthropathy. J Back Musculoskelet Rehabil. 2012;25(2):117-22. doi: 10.3233/BMR-2012-0319.
Clinical trial NCT03646279: Thoracolumbar Brace for Individuals With Parkinson's Disease
Official title: Pilot Investigation of a Thoracolumbar Brace for Individuals With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Lead sponsor: Duquesne University
Sponsor class: OTHER
Collaborators: name: AbiliLife
First posted: 2018-08-24
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single-subject A-B design
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This pilot study looked to see if a new brace would change the way people with Parkinson's Disease positioned their bodies. It also gathered information on the experience of wearing the brace.


Eligibility criteria: Inclusion Criteria:

* 50-80 years of age
* Diagnosed with Parkinson's Disease
* Participant self-reports mild difficulty with posture
* Independent in ambulation without an assistive device (i.e., no walker or cane)
* Able to give consent determined via telephone screen assessment or at minimum can follow simple directions
* Able to tolerate 5 minutes of standing or walking at a time per self-report

Exclusion Criteria:

* Rigid or fixed spine, as determined by self-report and use of thoracolumbar flexibility screen
* Symptoms present before the age of 50
* Other neurologic diagnosis, as determined by self-report
* Spinal surgery
* Lives in a nursing home or skilled facility
* Uncorrected vision loss
* Skin that is sensitive to tape or extremely fragile
* Recent surgery (within the last 3 months) that affects mobility, as determined by self-report
* Chest pain at rest or with activity per self report
* Shortness of breath with daily activity per self report
* Severe orthostatic hypotension assessed during in-person screen with sitting and standing blood pressure, evidenced by a 20-point drop in systolic blood pressure or 10-point drop in diastolic blood pressure and symptoms (e.g., dizziness) that don't resolve in 5 minutes.
* High blood pressure 180/110 resting or systolic blood pressure \<90 mmHG
* Resting heart rate \> 100 bpm or \<50 bpm
* Waist circumference \< 31" or \> 51" that would prevent proper fitting of CALIBRACE.

Primary outcomes:
measure: Postural Alignment - Neck Position
timeFrame: In a single session, 10 data points per phase were collected
measure: Postural Alignment - Trunk Position
timeFrame: In a single session, 10 data points per phase were collected
measure: Postural Alignment - Hip/Knee Position
timeFrame: In a single session, 10 data points per phase were collected
Secondary outcomes:
measure: Postural Sway - Center of pressure position
timeFrame: Single session
measure: Postural Sway - Center of pressure velocity
timeFrame: Single session
measure: Researcher Developed Survey on the Experience of the Brace - No Formal Name or Abbreviation
timeFrame: Single Session
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06475079: Correlation Between BMI and Craniovertebral Angle and Their Impact on Hand Grip Strength and Neck Functional Disability in Egyptian University Student
Official title: Correlation Between BMI and Craniovertebral Angle and Their Impact on Hand Grip Strength and Neck Functional Disability in Egyptian University Student
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Neck Pain
Lead sponsor: Ahram Canadian University
Sponsor class: OTHER
First posted: 2024-06-26
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 100 male and female patients Their ages will range from 20-30 years old. Their BMI will be between than 20- 30kg/m2, All of them suffer from mild degree of neck pain and They complain from neck pain for 1 month ago

Brief summary: Objective: To find the relation between cranio-vertebral angle and hand grip strength in university student mobile users.

Design: cross sectional study. Setting: Ahram Candian University Subjects:100 male and female university students with age ranged from 20 to 30 years old will participate in this study.

Intervention: cross sectional study to detect the relation between cranio-vertebral angle and hand grip strength in university student mobile users.

Main measures:

* FHP app (Pyeongtaek, South Korea) mobile application
* Hand dynamometer (the JAMAR® Hydraulic Hand) (Lupton-Smith et al.,2022)
* Mechanical height and weight scale
* Visual Analogue Scale
* Arabic Neck Disability Index Results: The results will be obtained via one-way analyses of variance (ANOVA).


Eligibility criteria: Inclusion Criteria:

* • Their ages will range from 20-30 years old.

  * Their BMI will be between than 20- 30kg/m2.
  * All of them suffer from mild degree of neck pain.
  * The subjects complain from neck pain for 1 month ago
* Exclusion criteria:

Exclusion criteria were a history of any of the following condition:

* inflammatory diseases or any rheumatic disorders,
* a history of vertebral fractures
* surgical spinal fixation.
* •any neurological disorders like MS

Primary outcomes:
measure: craniovertebral angle will measured by FHP (Forward Head Posture ) mobile application
timeFrame: baseline
measure: Hand grip strength will measured by Hand dynamometer (the JAMAR® Hydraulic Hand)
timeFrame: baseline
measure: Pain level will measured by Visual Analogue Scale
timeFrame: base line
measure: Neck functional disability will assess by Arabic Neck Disability Index
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: